Evidence for forebrain cholinergic neuronal loss in congenital ornithine transcarbamylase deficiency.
Congenital ornithine transcarbamylase (OTC) deficiency in humans results in failure to thrive, hypotonia, seizures and mental retardation. Neuropathologic evaluation reveals significant cerebral cortical atrophy, delayed myelination and Alzheimer type II astrocytosis. Using an animal model of congenital OTC deficiency, the sparse fur (spf) mouse, studies reveal convincing evidence of a loss of forebrain cholinergic neurons in this condition. Evidence includes (i) reduced activities of the cholinergic nerve terminal enzyme choline acetyltransferase (ChAT), (ii) a 25% loss of ChAT immunostaining, (iii) reduced high affinity transport of [3H]choline by cortical synaptosomes and (iv) a selective reduction in densities of presynaptic muscarinic M2 binding sites, in spf mouse brain compared to controls. A partial correction of the cholinergic deficit was observed following treatment with acetyl-L-carnitine. Possible mechanisms responsible for cholinergic neuronal loss in congenital OTC deficiency include decreased synthesis of the ChAT substrate acetyl CoA, impaired cerebral energy metabolism and NMDA receptor-mediated excitotoxicity. Loss of forebrain cholinergic neurons is consistent with the severe cognitive impairment characteristic of congenital OTC deficiency.
Butterworth
R F
RF
Neuroscience Research Unit, CHUM/Hôpital Saint-Luc, Montreal, Quebec, Canada. butterwr@medclin.umontreal.ca
D000818:Animals; D001921:Brain / Q000473:pathology; D016923:Cell Death / Q000502:physiology; D002795:Choline O-Acetyltransferase / Q000378:metabolism*; D004195:Disease Models, Animal; D006801:Humans; D009474:Neurons / Q000502:physiology*; D020163:Ornithine Carbamoyltransferase Deficiency Disease; D016548:Prosencephalon / Q000473:pathology / Q000503:physiopathology*
D002795:Choline O-Acetyltransferase